Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2026-03-11 @ 12:56 AM
Study NCT ID:
NCT01697293
Status:
TERMINATED
Last Update Posted:
2020-09-24
First Post:
2012-09-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Sponsor:
Prescient Therapeutics, Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-01
Start Date Type:
ACTUAL
Primary Completion Date:
2020-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-06
Completion Date Type:
ACTUAL
First Submit Date:
2012-09-13
First Submit QC Date:
None
Study First Post Date:
2012-10-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-09-22
Last Update Post Date:
2020-09-24
Last Update Post Date Type:
ACTUAL